Journal of Gastrointestinal Surgery

, Volume 12, Issue 2, pp 382–393 | Cite as

Pancreatic VIPomas: Subject Review and One Institutional Experience

  • Amir A. Ghaferi
  • Karen A. Chojnacki
  • William D. Long
  • John L. Cameron
  • Charles J. Yeo


VIPomas are rare pancreatic endocrine tumors associated with a well-defined clinical syndrome characterized by watery diarrhea, hypokalemia, and metabolic acidosis. The objective of this study was to review a single institution’s experience with VIPomas, as well as to review the English literature. A retrospective review of the Johns Hopkins pancreatic database revealed four cases of VIPoma, with three patients being male. All patients presented with watery diarrhea, hypokalemia, hypercalcemia, and acidosis. All patients had no family history of multiple endocrine neoplasia. Computed tomography revealed the primary pancreatic tumor in all patients, with three tumors located in the tail of the pancreas. One tumor involved the entire pancreas. Computed tomography and/or octreotide radionuclide scans identified hepatic metastasis in three patients. Mean serum vasoactive intestinal polypeptide levels were 683 pg/ml (range 293 to 1,500 pg/ml). All patients underwent resection of the pancreatic primary tumor. Two patients also had simultaneous liver resections. All patients had evidence of malignancy as defined by the presence of metastatic lymph nodes and/or hepatic metastases. Two patients had complete resolution of symptoms after surgical resection. One patient required radioablation of liver metastases and adjuvant octreotide therapy for control of symptoms. One patient died of progressive metastatic disease 96 months after surgery, whereas the other three remain alive. Extended, meaningful survival can be achieved for VIPoma patients, combining an aggressive surgical approach with additional strategies for treatment of unresected disease.


VIPomas Diarrhea Primary pancreatic tumor 


  1. 1.
    Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 1987;67:379.PubMedGoogle Scholar
  2. 2.
    Mekhijian HS, O’Dorisio TM. VIPoma syndrome. Semin Oncol 1987;14:282–291.Google Scholar
  3. 3.
    Capella C, Polak JM, Buffa R, Tapia FJ, Heitz P, Usellini L, Bloom SR, Solcia E. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer 1983;52(10):1860–1874.PubMedCrossRefGoogle Scholar
  4. 4.
    Ectors N. Pancreatic endocrine tumors: diagnostic pitfalls. Hepatogastroenterology 1999;46:679.PubMedGoogle Scholar
  5. 5.
    Priest WM, Alexander MK. Islet cell tumor of the pancreas with peptic ulceration, diarrhea and hypokalemia. Lancet 1957;273:1145–1147.PubMedCrossRefGoogle Scholar
  6. 6.
    Verner JV, Morrison AB. Islet cell tumour and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958;25:374.PubMedCrossRefGoogle Scholar
  7. 7.
    Bloom SR, Polak JM, Pearse AGE. Vasoactive intestinal peptide and watery-diarrhea syndrome. Lancet 1973;2:14–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Kane MG, O’Dorisio TM, Krejs GJ. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med 1983;309:1482–1485.PubMedCrossRefGoogle Scholar
  9. 9.
    Holst JJ, Fahrenkrug J, Knuhtsen S, Jensen SL, Poulsen SS, Nielsen OV. Vasoactive intestinal peptide (VIP) in the pig pancreas: role of VIPergic nerves in the control of fluid and bicarbonate secretion. Regul Pept 1984;8:245.PubMedCrossRefGoogle Scholar
  10. 10.
    Robberecht P, Conlon TP, Gardner JD. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3′,5′-monophosphate. J Biol Chem 1976;251:4635.PubMedGoogle Scholar
  11. 11.
    Barbezat GO, Grossman MI. Intestinal secretion: stimulation by peptides. Science 1971;174:422.PubMedCrossRefGoogle Scholar
  12. 12.
    Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol 1993;72:354.PubMedGoogle Scholar
  13. 13.
    Biancani P, Walsh JH, Behar J. Vasoactive intestinal polypeptide. A neurotransmitter for lower esophageal sphincter relaxation. J Clin Invest 1984;73:963.PubMedCrossRefGoogle Scholar
  14. 14.
    Usdin TB, Bonner TI, Mezey É. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994;135:2662.PubMedCrossRefGoogle Scholar
  15. 15.
    Koberstein B, Layer P, Balzer K, Muller MK, Singer MV, Goebell H. Paralytic ileus responding to somatostatin therapy: First manifestation of a VIPoma. Dig Dis Sci 1989;34(11):1803–1804.PubMedCrossRefGoogle Scholar
  16. 16.
    Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998;17(4):389–400.PubMedGoogle Scholar
  17. 17.
    Smith SL, Branton SA, Avino AJ, Martin JK, Klingler PJ, Thompson GB, Grant CS, van Heerden JA. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998;124(6):1050–1055.PubMedCrossRefGoogle Scholar
  18. 18.
    Peng SY, Li JT, Liu YB, Fang HQ, Wu YL, Peng CH, Wang XB, Qian HR. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas 2004;28(1):93–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Nikou GC, Toubanakis C, Niklolaou P, Giannatou E, Safioleas M, Mallas E, Polyzos A. VIPomas: An update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005;52:1259–1265.PubMedGoogle Scholar
  20. 20.
    Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999;116:1464–1486.PubMedCrossRefGoogle Scholar
  21. 21.
    Rood RP, DeLellis RA, Dayal Y, Donowitz M. Pancreatic cholera syndrome due to vasoactive intestinal polypeptide-producing tumor: further insights into the pathophysiology. Gastroenterology 1988;94:813.PubMedGoogle Scholar
  22. 22.
    Perry RR, Vinik AI. Clinical review 72: Diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995;80(8):2273–2278.PubMedCrossRefGoogle Scholar
  23. 23.
    Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Rouseu G, Couturier D, Bonnin A. Pancreatic tumors: Comparison of dual-phase helical CT and endoscopic sonography. Am J Roentgenol 1998;170(5):1315–1322.Google Scholar
  24. 24.
    King CM, Reznek RH, Dacie JE, Wass JA. Imaging islet cell tumours. Clin Radiol 1994;49(5):295–303.PubMedCrossRefGoogle Scholar
  25. 25.
    Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB. Detection of small functional islet cell tumors in the pancreas: Selection of MR imaging sequences for optimal sensitivity. Radiology 2000;214(2):483–490.PubMedGoogle Scholar
  26. 26.
    Capella C, Polak JM. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural and biochemical study of 32 cases. Cancer 1983;52:1860–1874.PubMedCrossRefGoogle Scholar
  27. 27.
    Jensen RT. Pancreatic endocrine tumors: Recent advances. Ann Oncol 1999;10:6 (Suppl).Google Scholar
  28. 28.
    Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty year experience. Surgery 1988;104:1011–1017.PubMedGoogle Scholar
  29. 29.
    O’Dorisio T, Mekhjian HA, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am 1989;18:545–556.PubMedGoogle Scholar
  30. 30.
    Kraenzlin ME, Ch’ng JL, Wood SM, Carr DH, Bloom SR. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985;88(1 Pt 1):185–187.PubMedGoogle Scholar
  31. 31.
    Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2):S111–S114.PubMedCrossRefGoogle Scholar
  32. 32.
    Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 1989;34:28S–39S.PubMedCrossRefGoogle Scholar
  33. 33.
    Cho KJ, Vinik AI. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation. Radiology 1990;177(2):549–553.PubMedGoogle Scholar
  34. 34.
    Cavallo-Perin P, De Paoli M, Guiso G, Sapino A, Papotti M, Coda R, Pagano G. A combined glucagonoma and VIPoma syndrome. First pathologic and clinical report. Cancer 1988;62(12):2576–2579.PubMedCrossRefGoogle Scholar
  35. 35.
    Christensen C. The somatostatin analogue SMS 201-995 in long-term treatment of vipoma. Case report. Acta Chir Scand 1989;155(10):541–543.PubMedGoogle Scholar
  36. 36.
    Tjon A Tham RT, Jansen JB, Falke TH, Roelfsema F, Griffioen G, van den Sluys Veer A, Lamers CB. MR, CT, and ultrasound findings of metastatic vipoma in pancreas. J Comput Assist Tomogr 1989;13(1):142–144.CrossRefGoogle Scholar
  37. 37.
    Venkatesh S, Vassilopoulou-Sellin R, Samaan NA. Somatostatin analogue: use in the treatment of vipoma with hypercalcemia Am J Med 1989;87(3):356–357.PubMedCrossRefGoogle Scholar
  38. 38.
    Maltese JY, Monge G, Giraud P, Salers P, Ouafik LH, Pelen F, Oliver C. Characterization of an alpha-amidating activity in a human pancreatic tumour secreting vasoactive intestinal peptide (VIP). Clin Endocrinol (Oxf) 1990;33(4):467–480.CrossRefGoogle Scholar
  39. 39.
    Bramley PN, Lodge JP, Losowsky MS, Giles GR. Treatment of metastatic vipoma by liver transplantation. Clin Transplant 1990;4(5 part 1):276–278; discussion 279.PubMedGoogle Scholar
  40. 40.
    Yanagi H, Kusunoki M, Sakanoue Y, Shoji Y, Yamamura T, Murai M, Kikkawa N, Utsunomiya J. Vipoma of the pancreas complicating ulcerative colitis. Am J Gastroenterol 1991;86(8):1066–1069.PubMedGoogle Scholar
  41. 41.
    Brunani A, Crespi C, De Martin M, Dubini A, Piolini M, Cavagnini F. Four year treatment with a long acting somatostatin analogue in a patient with Verner–Morrison syndrome. J Endocrinol Invest 1991;14(8):685–689.PubMedGoogle Scholar
  42. 42.
    Bani Sacchi T, Bani D, Biliotti G. Immunocytochemical and ultrastructural abnormalities of islet tissue in patients with VIP-producing tumors of the pancreas. Pancreas 1992;7(5):601–610.PubMedCrossRefGoogle Scholar
  43. 43.
    Udelsman R, Yeo CJ, Hruban RH, Pitt HA, Niederhuber JE, Coleman J, Cameron JL. Pancreaticoduodenectomy for selected pancreatic endocrine tumors. Surg Gynecol Obstet 1993;177(3):269–278.PubMedGoogle Scholar
  44. 44.
    Antonelli A, Gambuzza C, Bertoni F, Baschieri L. Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome. J Endocrinol Invest 1993;16(1):57–59.PubMedGoogle Scholar
  45. 45.
    Brunt LM, Mazoujian G, O’Dorisio TM, Wells SA Jr. Stimulation of vasoactive intestinal peptide and neurotensin secretion by pentagastrin in a patient with VIPoma syndrome. Surgery 1994;115(3):362–369.PubMedGoogle Scholar
  46. 46.
    Cesani F, Ernst R, Walser E, Villanueva-Meyer J. Tc-99m sestamibi imaging of a pancreatic VIPoma and parathyroid adenoma in a patient with multiple type I endocrine neoplasia. Clin Nucl Med 1994;19(6):532–534.PubMedCrossRefGoogle Scholar
  47. 47.
    Crowley PF, Slavin JL, Rode J. Massive amyloid deposition in pancreatic vipoma: a case report. Pathology 1996;28(4):377–379.PubMedCrossRefGoogle Scholar
  48. 48.
    Kirkpatrick AW, Hanna SS, Skinner BA. Surgical treatment of pancreatic cholera: a case report. Can J Surg 1996;39(2):155–158.PubMedGoogle Scholar
  49. 49.
    Sofka CM, Semelka RC, Marcos HB, Woosley JT. MR imaging of metastatic pancreatic VIPoma. Magn Reson Imaging 1997;15(10):1205–1208.PubMedCrossRefGoogle Scholar
  50. 50.
    Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P, Hubsch P, Dvorak M, Valent P, Niederle B. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J Nucl Med 1998;39(9):1575–1579.PubMedGoogle Scholar
  51. 51.
    Hengst K, Nashan B, Avenhaus W, Ullerich H, Schlitt HJ, Flemming P, Pichlmayr R, Domschke W. Metastatic pancreatic VIPoma: deteriorating clinical course and successful treatment by liver transplantation. Z Gastroenterol 1998;36(3):239–245.PubMedGoogle Scholar
  52. 52.
    Huang YH, Lee CH, Wu JC, Wang YJ, Chang FY, Lee SD. Functional pancreatic islet cell tumors with liver metastasis: the role of cytoreductive surgery and transcatheter arterial chemoembolization: a report of five cases. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61(12):748–754.Google Scholar
  53. 53.
    Sjoqvist U, Permert J, Lofberg R, Larsson J, Gadaleanu V, Adrian TE. Life threatening diarrhoea ultimately cured by surgery. Eur J Gastroenterol Hepatol 1998;10(11):963–967.PubMedCrossRefGoogle Scholar
  54. 54.
    Nguyen HN, Backes B, Lammert F, Wildberger J, Winograd R, Busch N, Rieband H, Matern S. Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Dig Dis Sci 1999;44(6):1148–1155.PubMedCrossRefGoogle Scholar
  55. 55.
    Samal SC, Paul AC, Venkateswari S, Nair S, Venkatramani S, Perakath B, Simon A, Chandy G, Kurian G. VIPoma of pancreas in a child. Indian J Gastroenterol 2000;19(4):194–195.PubMedGoogle Scholar
  56. 56.
    Masel SL, Brennan BA, Turner JH, Cullingford GL, Cullen DJ. Pancreatic vasoactive intestinal polypeptide-oma as a cause of secretory diarrhoea. J Gastroenterol Hepatol 2000;15(4):457–460.PubMedCrossRefGoogle Scholar
  57. 57.
    Thomason JW, Martin RS, Fincher ME. Somatostatin receptor scintigraphy: the definitive technique for characterizing vasoactive intestinal peptide-secreting tumors. Clin Nucl Med 2000;25(9):661–664.PubMedCrossRefGoogle Scholar
  58. 58.
    Yeh CN, Chen MF, Chen TC. Surgical treatment of pancreatic vasoactive intestinal polypeptide-secreting tumor: a case report. Hepatogastroenterology 2001;48(38):421–423.PubMedGoogle Scholar
  59. 59.
    Mortele KJ, Oei A, Bauters W, Timmermans F, Cuvelier C, Kunnen M, Ros PR. Dynamic gadolinium-enhanced MR imaging of pancreatic VIPoma in a patient with Verner–Morrison syndrome. Eur Radiol 2001;11(10):1952–1955.PubMedCrossRefGoogle Scholar
  60. 60.
    Smith CS, Houston M, Jensen B, Mlinar K, Toulson C, Tillotson LG. A 32-year-old man with copious, watery diarrhea. N C Med J 2001;62(3):134–139.PubMedGoogle Scholar
  61. 61.
    Shorter NA, Glick RD, Klimstra DS, Brennan MF, Laquaglia MP. Malignant pancreatic tumors in childhood and adolescence: The memorial Sloan–Kettering experience, 1967 to present. J Pediatr Surg 2002;37(6):887–892.PubMedCrossRefGoogle Scholar
  62. 62.
    Ichimura T, Kondo S, Okushiba S, Morikawa T, Katoh H. A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. Int J Gastrointest Cancer 2003;33(2–3):99–102.PubMedCrossRefGoogle Scholar
  63. 63.
    Drivas I, Mansberg R, Roberts JM. VIPoma: a rare cause of a pancreatic mass. Clin Nucl Med 2004;29(3):201–203.PubMedCrossRefGoogle Scholar
  64. 64.
    Schiller LR. Chronic diarrhea. Gastroenterology 2004;127(1):287–293.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2007

Authors and Affiliations

  • Amir A. Ghaferi
    • 1
  • Karen A. Chojnacki
    • 2
  • William D. Long
    • 2
  • John L. Cameron
    • 1
  • Charles J. Yeo
    • 2
  1. 1.Department of SurgeryJohns Hopkins Medical InstitutionsBaltimoreUSA
  2. 2.Department of SurgeryThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations